Abstract:
The present disclosure provides various core constructs. According to embodiments of the present disclosure, the core construct can be used to configure pharmaceutical molecules. In particular, the core construct may be conjugated with a functional element 5 via the click chemistry.
Abstract:
The present disclosure relates to anti-IgE antibodies that bind to novel antigenic epitopes of the CsmX domain, e.g., SVPHPRCHCGAGRA (SEQ ID NO:4) and the uses thereof in treating IgE-mediated diseases.
Abstract translation:本公开涉及结合CsmX结构域的新型抗原表位(例如SVPHPRCHCGAGRA(SEQ ID NO:4))的抗IgE抗体及其在治疗IgE介导的疾病中的用途。
Abstract:
The present disclosure provides various core constructs. According to embodiments of the present disclosure, the core construct can be used to configure pharmaceutical molecules. In particular, the core construct may be conjugated with a functional element via the click chemistry.
Abstract:
The present disclosure provides various core constructs. According to embodiments of the present disclosure, the core construct can be used to configure pharmaceutical molecules. In particular, the core construct may be conjugated with a functional element 5 via the click chemistry.
Abstract:
The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
Abstract:
The present disclosure provides various core constructs. According to embodiments of the present disclosure, the core construct can be used to configure pharmaceutical molecules. In particular, the core construct may be conjugated with a functional element via the click chemistry.
Abstract:
The present disclosure provides various molecular constructs having a targeting element and an effector element. Uses for treating various diseases using such molecular constructs are also disclosed.
Abstract:
The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
Abstract:
The present disclosure relates to anti-IgE antibodies that bind to novel antigenic epitopes of the CsmX domain, e.g., SVPHPRCHCGAGRA (SEQ ID NO: 4) and the uses thereof in treating IgE-mediated diseases.